Cigna Group Past Earnings Performance
Past criteria checks 0/6
Cigna Group's earnings have been declining at an average annual rate of -5.3%, while the Healthcare industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 8% per year. Cigna Group's return on equity is 7.9%, and it has net margins of 1.3%.
Key information
-5.3%
Earnings growth rate
-0.05%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 8.0% |
Return on equity | 7.9% |
Net Margin | 1.3% |
Next Earnings Update | 30 Jan 2025 |
Recent past performance updates
Recent updates
Cigna: Buy The Drop On This Undervalued Growth Stock
Jan 18The Cigna Group's (NYSE:CI) Earnings Haven't Escaped The Attention Of Investors
Dec 29Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Dec 13These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well
Oct 14Cigna: This Dividend Grower Could Be Worth Buying Now
Sep 26Returns On Capital Are Showing Encouraging Signs At Cigna Group (NYSE:CI)
Sep 26Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
Sep 19The Price Is Right For The Cigna Group (NYSE:CI)
Sep 08Cigna Group: Services Focus Leads To Outperformance
Jul 29Cigna: Game Over For PBMs?
Jul 12Cigna Group (NYSE:CI) Has A Somewhat Strained Balance Sheet
Jun 14Cigna: Will Benefit From Lower Medicaid Enrollments
Jun 11The Cigna Group (NYSE:CI) Not Lagging Market On Growth Or Pricing
May 27Cigna: An Up-And-Coming Dividend Growth Stock To Buy Now
May 13Cigna Group's (NYSE:CI) Soft Earnings Don't Show The Whole Picture
May 09Here's Why We Think The Cigna Group's (NYSE:CI) CEO Compensation Looks Fair for the time being
Apr 18Cigna: Time To Sell The Stock After A 50% Return? No, Here's Why
Apr 09Returns Are Gaining Momentum At Cigna Group (NYSE:CI)
Apr 05Cigna Continues To Reap Gains From A Shrewd Acquisition Made In 2018
Apr 01Cigna: Trimming The Fat And Staying Focused
Mar 05Cigna: Big Buybacks And Total Return Potential
Feb 26Cigna Group (NYSE:CI) Is Increasing Its Dividend To $1.40
Feb 05Cigna Q4 Preview: The Analysts' Whisper - Deciphering Cigna's Next Big Leap
Jan 29We Think Cigna Group (NYSE:CI) Can Stay On Top Of Its Debt
Jan 25Why Dividend Growth Investors Should Buy Cigna
Jan 18Cigna: Sentiment And Fundamentals On Their Side
Dec 21Cigna's Merger Fumble: A Festive Financial Rebound
Dec 11Humana And Cigna Topple On Rumors Of An Unlikely Union
Nov 30Cigna Delivering Growth At A Great Price
Nov 13Cigna: Too Cheap To Ignore
Oct 24Cigna: Buy Rating Driven By Undervaluation & Revenue Growth
Oct 01Cigna: Seizing Opportunities And Managing Risks In The Healthcare Landscape
Sep 14Cigna Group: Weaker Than Peers But Still A Buy
Aug 27Cigna: Buy During The Next Correction (Technical Analysis)
Aug 08Cigna: Buy While It's Still Cheap And Not Loved
Jun 29Revenue & Expenses Breakdown
How Cigna Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 229,747 | 3,039 | 14,622 | 0 |
30 Jun 24 | 216,008 | 3,708 | 14,685 | 0 |
31 Mar 24 | 204,145 | 3,620 | 14,496 | 0 |
31 Dec 23 | 195,187 | 5,164 | 14,370 | 0 |
30 Sep 23 | 189,866 | 5,328 | 14,050 | 0 |
30 Jun 23 | 186,031 | 6,677 | 13,609 | 0 |
31 Mar 23 | 182,808 | 6,774 | 13,421 | 0 |
31 Dec 22 | 180,031 | 6,704 | 13,110 | 0 |
30 Sep 22 | 180,028 | 6,627 | 13,042 | 0 |
30 Jun 22 | 179,185 | 5,491 | 12,999 | 0 |
31 Mar 22 | 176,986 | 5,401 | 12,748 | 0 |
31 Dec 21 | 174,267 | 5,370 | 12,791 | 0 |
30 Sep 21 | 170,397 | 8,384 | 13,296 | 0 |
30 Jun 21 | 167,028 | 8,151 | 13,402 | 0 |
31 Mar 21 | 163,141 | 8,438 | 13,697 | 0 |
31 Dec 20 | 160,550 | 8,458 | 13,660 | 0 |
30 Sep 20 | 157,009 | 5,300 | 13,329 | 0 |
30 Jun 20 | 154,629 | 5,263 | 13,467 | 0 |
31 Mar 20 | 154,168 | 4,917 | 13,332 | 0 |
31 Dec 19 | 153,743 | 5,104 | 13,315 | 0 |
30 Sep 19 | 129,660 | 4,271 | 12,391 | 0 |
30 Jun 19 | 102,510 | 3,692 | 12,107 | 0 |
31 Mar 19 | 75,145 | 3,090 | 11,651 | 0 |
31 Dec 18 | 48,569 | 2,637 | 11,141 | 0 |
30 Sep 18 | 44,969 | 2,759 | 18,350 | 0 |
30 Jun 18 | 44,001 | 2,547 | 15,343 | 0 |
31 Mar 18 | 42,949 | 2,554 | 12,639 | 0 |
31 Dec 17 | 42,043 | 2,237 | 9,830 | 0 |
30 Sep 17 | 41,332 | 2,353 | 54 | 0 |
30 Jun 17 | 40,723 | 2,249 | 0 | 0 |
31 Mar 17 | 40,258 | 1,946 | 0 | 0 |
31 Dec 16 | 40,007 | 1,867 | 9,750 | 0 |
30 Sep 16 | 39,252 | 1,911 | 0 | 0 |
30 Jun 16 | 38,761 | 2,002 | 0 | 0 |
31 Mar 16 | 38,293 | 2,080 | 0 | 0 |
31 Dec 15 | 37,876 | 2,094 | 0 | 0 |
30 Sep 15 | 37,276 | 2,135 | 0 | 0 |
30 Jun 15 | 36,644 | 2,122 | 0 | 0 |
31 Mar 15 | 35,885 | 2,107 | 0 | 0 |
31 Dec 14 | 34,914 | 2,102 | 0 | 0 |
30 Sep 14 | 34,098 | 1,996 | 0 | 0 |
30 Jun 14 | 33,407 | 2,015 | 0 | 0 |
31 Mar 14 | 32,654 | 1,947 | 0 | 0 |
Quality Earnings: CI has a large one-off loss of $2.0B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: CI's current net profit margins (1.3%) are lower than last year (2.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CI's earnings have declined by 5.3% per year over the past 5 years.
Accelerating Growth: CI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CI had negative earnings growth (-43%) over the past year, making it difficult to compare to the Healthcare industry average (11.8%).
Return on Equity
High ROE: CI's Return on Equity (7.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/19 11:20 |
End of Day Share Price | 2025/01/17 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The Cigna Group is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Argus Research Company |
Hua Ha | Baird |
Ishan Majumdar | Baptista Research |